Wudhikarn K, et al. - Since peripheral T cell lymphoma (PTCL) is relatively uncommon compared to B cell lymphoma, however, it generally carries worse prognosis, researchers examined event free survival at 12 months (EFS12) and 24 months (EFS24) as tools to stratify survival outcome in PTCL patients. According to findings, of 353 PTCL, 292 received multiagent chemotherapy. Data reported that median age at diagnosis was 49 years. Investigators found that median EFS and overall survival [defined as time from a specific timepoints either diagnosis or EFS12 to death] of patients who received treatment were 16.3 and 27.7 months. A total of 138 patients developed an event within 12 months of initiation of treatment (failed to reach EFS12). The authors concluded that EFS12 and EFS24 are strong endpoints of a surrogate in PTCL treatment outcomes.